(Q55029808)

English

Temozolomide Plus Bevacizumab in Elderly Patients with Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial (ATAG).

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

15 June 2018

http://europepmc.org/abstract/PMC/5947454

Temozolomide Plus Bevacizumab in Elderly Patients with Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial (ATAG). (English)

1 reference

Europe PubMed Central

PMC publication ID

15 June 2018

http://europepmc.org/abstract/PMC/5947454

phase II clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

object named as

Emilie Le Rhun

13

0 references

object named as

Olivier L Chinot

3

0 references

Alexandra Benouaich-Amiel

12

object named as

Alexandra Benouaich-Amiel

1 reference

Europe PubMed Central

15 June 2018

PMC publication ID

11

object named as

Didier Frappaz

1 reference

Europe PubMed Central

PMC publication ID

15 June 2018

http://europepmc.org/abstract/PMC/5947454

author name string

Germán Reyes-Botero

1

1 reference

Europe PubMed Central

PMC publication ID

15 June 2018

http://europepmc.org/abstract/PMC/5947454

Stéphanie Cartalat-Carel

2

1 reference

Europe PubMed Central

PMC publication ID

15 June 2018

http://europepmc.org/abstract/PMC/5947454

Maryline Barrie

4

1 reference

Europe PubMed Central

PMC publication ID

15 June 2018

http://europepmc.org/abstract/PMC/5947454

Luc Taillandier

5

1 reference

Europe PubMed Central

PMC publication ID

15 June 2018

http://europepmc.org/abstract/PMC/5947454

Patrick Beauchesne

6

1 reference

Europe PubMed Central

PMC publication ID

15 June 2018

http://europepmc.org/abstract/PMC/5947454

Isabelle Catry-Thomas

7

1 reference

Europe PubMed Central

PMC publication ID

15 June 2018

http://europepmc.org/abstract/PMC/5947454

Jérôme Barrière

8

1 reference

Europe PubMed Central

PMC publication ID

15 June 2018

http://europepmc.org/abstract/PMC/5947454

Jean-Sebastien Guillamo

9

1 reference

Europe PubMed Central

PMC publication ID

15 June 2018

http://europepmc.org/abstract/PMC/5947454

Michel Fabbro

10

1 reference

Europe PubMed Central

PMC publication ID

15 June 2018

http://europepmc.org/abstract/PMC/5947454

Chantal Campello

14

1 reference

Europe PubMed Central

PMC publication ID

15 June 2018

http://europepmc.org/abstract/PMC/5947454

Isabelle Tennevet

15

1 reference

Europe PubMed Central

PMC publication ID

15 June 2018

http://europepmc.org/abstract/PMC/5947454

François Ghiringhelli

16

1 reference

Europe PubMed Central

PMC publication ID

15 June 2018

http://europepmc.org/abstract/PMC/5947454

Marie-Laure Tanguy

17

1 reference

Europe PubMed Central

PMC publication ID

15 June 2018

http://europepmc.org/abstract/PMC/5947454

Karima Mokhtari

18

1 reference

Europe PubMed Central

PMC publication ID

15 June 2018

http://europepmc.org/abstract/PMC/5947454

Jérôme Honnorat

19

1 reference

Europe PubMed Central

PMC publication ID

15 June 2018

http://europepmc.org/abstract/PMC/5947454

Jean-Yves Delattre

20

1 reference

Europe PubMed Central

PMC publication ID

15 June 2018

http://europepmc.org/abstract/PMC/5947454

publication date

22 February 2018

1 reference

Europe PubMed Central

PMC publication ID

15 June 2018

http://europepmc.org/abstract/PMC/5947454

1 reference

Europe PubMed Central

PMC publication ID

15 June 2018

http://europepmc.org/abstract/PMC/5947454

23

1 reference

Europe PubMed Central

PMC publication ID

15 June 2018

http://europepmc.org/abstract/PMC/5947454

5

1 reference

Europe PubMed Central

PMC publication ID

15 June 2018

http://europepmc.org/abstract/PMC/5947454

524-e44

1 reference

Europe PubMed Central

PMC publication ID

15 June 2018

http://europepmc.org/abstract/PMC/5947454

Systemic glucocorticoid therapy: a review of its metabolic and cardiovascular adverse events.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5947454

16 June 2018

Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5947454

16 June 2018

A randomized trial of bevacizumab for newly diagnosed glioblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5947454

16 June 2018

Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5947454

16 June 2018

CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5947454

16 June 2018

Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5947454

16 June 2018

Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5947454

16 June 2018

Recursive partitioning analysis of prognostic factors for glioblastoma patients aged 70 years or older

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5947454

16 June 2018

Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5947454

16 June 2018

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5947454

16 June 2018

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5947454

16 June 2018

International Atomic Energy Agency Randomized Phase III Study of Radiation Therapy in Elderly and/or Frail Patients With Newly Diagnosed Glioblastoma Multiforme

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5947454

13 August 2018

Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEF†.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5947454

13 August 2018

Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5947454

13 August 2018

Radiotherapy for glioblastoma in the elderly.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5947454

13 August 2018

Descriptive epidemiology of cerebral gliomas in France.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5947454

13 August 2018

Identifiers

10.1634/THEONCOLOGIST.2017-0689

1 reference

Europe PubMed Central

PMC publication ID

15 June 2018

http://europepmc.org/abstract/PMC/5947454

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

15 June 2018

http://europepmc.org/abstract/PMC/5947454

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

15 June 2018

http://europepmc.org/abstract/PMC/5947454

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q55029808&oldid=1898850750"